Catheter-Based Local Delivery of Therapeutics to the Lungs for Severe or Critically Ill Patients with COVID-19-Reference-Cited by-同舟云学术

Catheter-Based Local Delivery of Therapeutics to the Lungs for Severe or Critically Ill Patients with COVID-19

Published:2021-02-09 Issue: Volume: Page:46-51
ISSN:2513-8634
Container-title:EMJ Innovations
language:en
Short-container-title:EMJ Innov

Author:

George Dangas George Dangas¹,Christopher J. White Christopher J. White²,Nodar Kipshidze Nodar Kipshidze³,Jawed Fareed Jawed Fareed⁴,Patrick Iversen Patrick Iversen⁵,Antonio Colombo Antonio Colombo⁶,Nicholas Kipshidze Nicholas Kipshidze⁷

Affiliation:

1. Icahn School of Medicine at Mount Sinai, New York City, New York, USA

2. Ochsner Clinical School, University of Queensland, Australia and Ochsner Medical Center, New Orleans, Louisiana, USA

3. NYU Langone Health, New York, New York, USA

4. Department of Pathology and Laboratory Medicine and Department of Pharmacology and Neuroscience, Cardiovascular Research Institute, Loyola University Chicago, Health Sciences Division, Maywood, Illinois, USA

5. USAMRID, Fort Detrick, Maryland, USA

6. University Vita e Salute in San Raffaele Hospital and Columbus Hospitals, Milan, Italy

7. NY Cardiovascular Research, New York City, New York, USA

Publisher

European Medical Group

Reference33 articles.

1. Wang D et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9.

2. Young BE et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA. 2020;323(15):1488-94.

3. Han C et al. Digestive symptoms in COVID-19 patients with mild disease severity: clinical presentation, stool viral RNA testing, and outcomes. Am J Gastroenterol. 2020;115(6):916-23.

4. Mao L et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683-90.

5. Hoffmann M et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-80.e8.